for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi SA

SASY.PA

Latest Trade

85.53EUR

Change

0.42(+0.49%)

Volume

1,834,494

Today's Range

85.13

 - 

86.16

52 Week Range

74.92

 - 

91.14

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
85.11
Open
85.74
Volume
1,834,494
3M AVG Volume
35.61
Today's High
86.16
Today's Low
85.13
52 Week High
91.14
52 Week Low
74.92
Shares Out (MIL)
1,252.54
Market Cap (MIL)
107,534.10
Forward P/E
13.46
Dividend (Yield %)
3.76

Next Event

Sanofi SA at EBD Group BIO-Europe (Virtual)

Latest Developments

More

Sanofi/Regeneron: Phase 3 trial results show Dupixent® (dupilumab) reduced itches and skin lesions

Sanofi Provides New Long-Term Data Brain-Penetrant Tolebrutinib

Mirati To Join Sanofi On Study Evaluating Adagrasib With SHP2 Inhibitor In KRAS G12C-Mutated Lung Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sanofi SA

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

Industry

Biotechnology & Drugs

Contact Info

54 rue la Boetie

75008

France

+33.1.53774000

https://www.sanofi.com/

Executive Leadership

Serge Weinberg

Independent Chairman of the Board

Paul Hudson

Chief Executive Officer, Member of the Executive Committee, Director

Jean- Baptiste Chasseloup De Chatillon

Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Natalie Bickford

Chief Human Resource Officer, Executive Vice President, Member of the Executive Committee

Karen Linehan

Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee

Key Stats

2.07 mean rating - 30 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

34.5K

2019

36.1K

2020

36.0K

2021(E)

38.0K
EPS (EUR)

2018

5.470

2019

5.990

2020

5.860

2021(E)

6.322
Price To Earnings (TTM)
18.40
Price To Sales (TTM)
2.86
Price To Book (MRQ)
1.69
Price To Cash Flow (TTM)
14.56
Total Debt To Equity (MRQ)
34.31
LT Debt To Equity (MRQ)
30.40
Return on Investment (TTM)
6.12
Return on Equity (TTM)
5.10

Latest News

Latest News

Sanofi says its flu vaccine can be co-administered with Moderna's COVID-19 shot

Sanofi SA's flu vaccine can be safely given along with Moderna Inc's COVID-19 vaccine, the French drugmaker said on Wednesday, citing study data.

Sanofi says good results from flu vaccine with mRNA booster study

French healthcare company Sanofi said on Wednesday that it had found positive results from the first study into a high-dose influenza vaccine with a COVID-19 mRNA booster.

Sanofi ditches mRNA COVID-19 vaccine after rivals' success

Sanofi is dropping plans for its own mRNA-based COVID-19 vaccine because of the dominance achieved by BioNTech-Pfizer and Moderna in using the technology to fight the pandemic, the company said on Tuesday.

France's Sanofi to buy U.S. biopharma firm Kadmon in $1.9 billion deal

French drugmaker Sanofi said on Wednesday it would buy U.S. biopharmaceutical company Kadmon Holdings for 1.9 billion dollars, one month after announcing the purchase of another US biotech, Translate Bio, for $3.2 billion.

France's Sanofi to buy U.S. biopharma firm Kadmon in $1.9 bln deal

French drugmaker Sanofi SA has agreed to buy U.S. biopharmaceutical company Kadmon Holdings Inc in a $1.9 billion deal, the companies said on Wednesday.

U.S. FDA approves another Sanofi drug for rare muscle disorder Pompe disease

Sanofi's treatment for muscle disorder Pompe disease received the U.S. health regulator's nod on Friday, strengthening the French drugmaker's hold on the market for drugs to treat the rare but potentially fatal disease.

Analysis-Sanofi's COVID-19 vaccine setback, drug pipeline cast long shadow

Pharmaceutical company Sanofi remains under pressure to launch new drugs and overcome setbacks in the COVID-19 vaccine race, despite a $3.2 billion deal to tighten its grip on promising mRNA technology.

Sanofi bets on mRNA vaccines beyond COVID in $3.2 billion Translate Bio deal

Sanofi has agreed to buy U.S. biotech company Translate Bio in a $3.2 billion deal, as it bets on next-generation mRNA vaccine technology beyond the COVID-19 pandemic, confirming a Reuters exclusive report.

Exclusive-Sanofi offers to buy U.S. biotech, mRNA partner Translate Bio -sources

Sanofi has offered to buy U.S. biotech company Translate Bio, two sources familiar with the situation said on Monday, as the French drugmaker bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.

Sanofi bets on mRNA vaccines beyond COVID in $3.2 billion Translate Bio deal

Sanofi has agreed to buy U.S. biotech company Translate Bio in a $3.2 billion deal, as it bets on next-generation mRNA vaccine technology beyond the COVID-19 pandemic, confirming a Reuters exclusive report.

Sanofi confirms $3.2 billion offer to buy U.S. biotech firm Translate Bio

French drugmaker Sanofi said it had made a $3.2 billion offer to buy U.S. biotech company Translate Bio, as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.

EXCLUSIVE-Sanofi offers to buy U.S. mRNA partner Translate Bio -sources

Sanofi has offered to buy U.S. biotech company Translate Bio, two sources familiar with the situation said on Monday, as the French drugmaker bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.

Sanofi raises profit forecast after second quarter beat

Sanofi raised its 2021 profit forecast on Thursday after its vaccines and star eczema treatment Dupixent helped it beat second-quarter results expectations.

Sanofi raises profit forecasts after strong second quarter

Sanofi raised its 2021 outlook after its vaccines and star eczema treatment Dupixent helped it post better-than-expected second-quarter results on Thursday. The French drugmaker said it was now targeting earnings per share to grow around 12% at constant exchange rates this...

EU begins real-time review of Sanofi-GSK COVID-19 vaccine

Europe's drug regulator said on Tuesday it had started a real-time review of the COVID-19 vaccine developed by French drugmaker Sanofi and Britain's GlaxoSmithKline, the fifth shot currently under such a review.

BRIEF-Sanofi: rolling reviews of COVID-19 recombinant vaccine to start soon in UK, Canada and Singapore

* SANOFI SAYS 'ROLLING REVIEWS" OF ITS COVID-19 RECOMBINANT VACCINE ARE ABOUT TO START IN BRITAIN, CANADA AND SINGAPORE IN THE "COMING DAYS"

EU begins real-time review of Sanofi-GSK COVID-19 vaccine

Europe's drug regulator said on Tuesday it had started a real-time review of the COVID-19 vaccine being developed by French drugmaker Sanofi and Britain's GlaxoSmithKline.

BRIEF-EU Drugs Regulator Starts Rolling Review Of Sanofi/GSK COVID-19 Vaccine

* EMA: EMA STARTS ROLLING REVIEW OF COVID-19 VACCINE VIDPREVTYN: 20/07/2021

Sanofi can't escape second bellwether trial over Taxotere

Sanofi has lost a bid for summary judgment in the second bellwether case in multidistrict litigation over its chemotherapy drug Taxotere, after a federal judge ruled that a recent appeals court decision did not change the legal standard for whether Sanofi's conduct caused...

Brazil's Hypera buys Latam OTC products from Sanofi for $190 million

Brazilian pharmaceutical company Hypera SA has acquired 12 over-the-counter (OTC) and prescription brands in Latin America from France's Sanofi SA for $190.3 million, the company said in a securties filing.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up